

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GP 1615

In re Patent Application of

Atty Dkt. 121-160

PARIKH et al

C# M#

Serial No. 09/281,430

Group Art Unit: 1615

Filed: March 30, 1999

Examiner: Ware, T.

Title: ANTICANCER COMPOSITIONS

Date: October 10, 2000

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

OCT. 16 2000

TECH CENTER 1600 10/10/2000

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	26	minus highest number			
previously paid for	26	(at least 20) =	0	x	\$ 18.00

Independent claims after amendment	6	minus highest number			
previously paid for	6	(at least 3) =	0	x	\$ 80.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper)		\$	0.00
--	--	----	------

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months)		\$	0.00
--	--	----	------

Terminal disclaimer enclosed, add \$ 110.00		\$	0.00
---	--	----	------

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00)		\$	0.00
<input type="checkbox"/> Please enter the previously unentered , filed			
<input type="checkbox"/> Submission attached			
<input type="checkbox"/> Request for Continued Examination pursuant to 37 C.F.R. § 1.114 (\$710.00)		\$	0.00
<input type="checkbox"/> Please enter the previously unentered , filed			
<u>or</u> <input type="checkbox"/> Required submission attached			

Subtotal	\$	0.00
-----------------	----	-------------

If "small entity," then enter half (1/2) of subtotal and subtract		-\$	0.00
<input type="checkbox"/> Statement filed herewith			

Rule 56 Information Disclosure Statement Filing Fee (\$240.00)		\$	0.00
--	--	----	------

Assignment Recording Fee (\$40.00)		\$	0.00
------------------------------------	--	----	------

Other:			0.00
--------	--	--	-------------

TOTAL FEE ENCLOSED	\$	0.00
---------------------------	----	-------------

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
ARC:pfc

NIXON & VANDERHYE P.C.
By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

PARIKH et al

Serial No. 09/281,430

Filed: March 30, 1999

For: ANTICANCER COMPOSITIONS



Atty. Ref.: 121-160

Group: 1615

Examiner: Ware, T.

*TK
Atkinson
10/20/00*

* * * * *

October 10, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

Responsive to the Official Action dated July 17, 2000, please amend the above-identified application as follows:

IN THE CLAIMS

1. (Amended) A pharmaceutical composition comprising an anticancer drug as active ingredient dissolved in a non-aqueous carrier system [comprising] consisting essentially of at least one hydrophobic component, a hydrophilic component and at least one surfactant, wherein the hydrophobic component is selected from triglycerides, diglycerides, monoglycerides, free fatty acids, and fatty acid esters[and derivatives thereof], individually or in combination and wherein the hydrophilic component is a